论文部分内容阅读
目的了解2007年-2008年成都地区17家医院抗肿瘤药物的使用情况。方法以销售金额、用药频度(DDDs)对2007年、2008年成都地区17家医院抗肿瘤药物消耗数据进行分类统计、综合分析、对比。结果 2008年成都地区17家医院抗肿瘤药物用药金额增长幅度较大,各亚类抗肿瘤药物中其它类抗肿瘤药物类、植物来源的抗肿瘤药、抗代谢药金额排序依次占前3位。销售金额前100位药物中,肿瘤药物占据8位,大多数是其它类抗肿瘤药物,且其用药频度也靠前。结论抗肿瘤药物用药金额和用药量都将快速增长,其中其它类抗肿瘤药物和植物来源的抗肿瘤药的发展尤被看好。
Objective To understand the use of anticancer drugs in 17 hospitals in Chengdu from 2007 to 2008. Methods According to the sales amount and medication frequency (DDDs), the anti-tumor drug consumption data of 17 hospitals in Chengdu in 2007 and 2008 were classified and statistically analyzed. Results In 2008, the amount of antitumor drugs in 17 hospitals in Chengdu increased greatly. The antitumor drugs and antineoplastic drugs and antimetabolites in each subclass of anticancer drugs ranked the top 3 in turn. Sales amount of the top 100 drugs, cancer drugs occupy 8, most of them are other types of anti-cancer drugs, and its frequency of medication also in front. Conclusion The amount of anti-tumor drugs and dosage will rapidly increase, of which other types of anti-tumor drugs and plant-derived anti-tumor drugs are particularly promising.